Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 15 Jun 2015 |
| 357,560 Orion Corporation A shares converted into B shares | 18 May 2015 |
| Orion Group Interim Report January-March 2015 | 29 Apr 2015 |
| 200,647 Orion Corporation A shares converted into B shares | 27 Apr 2015 |
| Orion upgrades full-year outlook for 2015 | 24 Apr 2015 |